Trial Profile
A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; TG-02-Targovax (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Targovax
- 13 Jun 2019 Status changed from recruiting to discontinued.
- 26 Feb 2019 Planned number of patients changed from 20 to 16.
- 14 Feb 2019 According to a Targovax media release, immune activation and mechanistic data (TG monotherapy cohort) is expected in 1H 2019.